PDD00017273


Up to 10 uM, or 10X the cellular IC50 depending on the cell line
Probe Availability
Probe Information
In vitro validation
Biochemical selectivity against safety targets (% inhibition at 10 µM, binding assay Eurofins Panlabs):
Adenosine A1=1%,
Adenosine A2A=-1%,
Adrenergic a1A=-5%,
Adrenergic a1B=7%,
Adrenergic a2A=10%,
Adrenergic β1=-9%,
Adrenergic β2=-9%,
Calcium Channel=L Type=16%,
Cannabinoid CB1=21%,
Dopamine D1=6%,
Dopamine D2S=-9%,
GABAA=Flunitrazepam Central=4%,
GABAA=Muscimol Central=3%,
Glutamate=NMDA=4%,
Histamine H1=-6%,
Imidazoline I2=Central=-18%,
Muscarinic M2 =-1%,
Muscarinic M3 =3%,
Nicotinic Acetylcholine=3%,
Nicotinic Acetylcholine=a1=-3%,
Opiate µ(OP3=MOP)=-6%,
Phorbol Ester=-11%,
Potassium Channel [KATP]=5%,
Potassium Channel hERG=12%,
Prostanoid EP4=11%,
Rolipram=16%,
Serotonin (5-Hydroxytryptamine) 5-HT2B=4%,
Sigma σ1=15%,
Sodium Channel site 2=6%,
Transporter=Norepinephrine (NET)=20%,
Acetyl Cholinesterase=-1%,
Cyclooxegenase COX-2=-2%,
Phosphodiesterase PDE4=17%,